Revenue
8.65 million USD
2025 · USD
Exact inputs and evidence
- Revenue: 8646844 USD Source
Market value is not computed: this company’s US price is per depositary share, not per ordinary share.
Annual consolidated revenue for 2025: about USD 8.647M, using the latest reported figures. The previous period, 2024, was about USD 8.185M.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
This issuer has insider filings in the store, but no transaction in this window or code group.
7766738 USD
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-05-19.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
USD 8.19 million
–
Current period
USD 8.65 million
–
8646844 − 8185146 = 461698 USD
8185146 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source8646844 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 2.37 million
–
Current period
USD 6.4 million
–
6403463 − 2372842 = 4030621 USD
2372842 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source6403463 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 2.08 million
–
Current period
−USD 6.74 million
–
-6739075 − 2080387 = -8819462 USD
2080387 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-6739075 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | 23544652 | 13349064 Derived | 10195588 | 184411 Derived | 10011177 | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 6711990 | 4751061 Derived | 1960929 | -292780 Derived | 2253709 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 8185146 | 6189779 Derived | 1995367 | -377475 Derived | 2372842 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 8646844 | 2879104 Derived | 5767740 | -635723 Derived | 6403463 | Unavailable | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Revenue | 23544652 |
|
| 2023 | Revenue | 6711990 |
|
| 2024 | Revenue | 8185146 |
|
| 2025 | Revenue | 8646844 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Year over year | No prior comparable period |
|
| 2023 | Year over year | -71.5% |
|
| 2024 | Year over year | 21.9% |
|
| 2025 | Year over year | 5.6% |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Operating margin | 43.3% |
|
| 2023 | Operating margin | 29.2% |
|
| 2024 | Operating margin | 24.4% |
|
| 2025 | Operating margin | 66.7% |
|
| 2022 | Net margin | 42.5% |
|
| 2023 | Net margin | 33.6% |
|
| 2024 | Net margin | 29% |
|
| 2025 | Net margin | 74.1% |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Operating cash flow | 4448846 |
|
| 2023 | Operating cash flow | 898367 |
|
| 2024 | Operating cash flow | 2080387 |
|
| 2025 | Operating cash flow | -6739075 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2023 | Liabilities / assets | 6.3% |
|
| 2024 | Liabilities / assets | 9.1% |
|
| 2025 | Liabilities / assets | 0.3% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2023 | Current assets / current liabilities | 15.86× |
|
| 2024 | Current assets / current liabilities | 10.71× |
|
| 2025 | Current assets / current liabilities | 344.31× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | USD 10.01 million Exact valueExact value: 10011177 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 4.45 million Exact valueExact value: 4448846 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | USD 2.25 million Exact valueExact value: 2253709 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 898,367 Exact valueExact value: 898367 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | USD 2.37 million Exact valueExact value: 2372842 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.08 million Exact valueExact value: 2080387 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | USD 6.4 million Exact valueExact value: 6403463 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 6.74 million Exact valueExact value: -6739075 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
10 filings · 174 latest values · 174 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001982708, 1982708, NNNN, edgar:1982708
Also known as Anbio Biotechnology